Antibody-mediated enhancement of HIV-1 and HIV-2 production from BST-2/tetherin-positive cells

Journal of Virology

Volumn 85, Issue 22, 2011, Pages 11981-11994

  Miyagi, Eri ^a   Andrew, Amy ^a   Kao, Sandra ^a   Yoshida, Takeshi ^a   Strebel, Klaus ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE ANTIGEN; BST 2 ANTIBODY; PROTEIN ANTIBODY; PROTEIN BST 2; TETHERIN; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; CELL STRAIN; CELL STRAIN 293T; CELL SURFACE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DIMERIZATION; FLOTATION; HELA CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; INHIBITION KINETICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; VIRION; VIROGENESIS; VIRUS CAPSID; VIRUS RELEASE; VIRUS SHEDDING;

ANTIBODIES; ANTIGENS, CD; CELL LINE; GPI-LINKED PROTEINS; HIV-1; HIV-2; HUMANS; VIRUS RELEASE;

ARENAVIRUS; HERPESVIRIDAE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; MARBURGVIRUS;

EID: 80655146209     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.05176-11     Document Type: Article

References (65)

1. Abada, P., B. Noble, and P. M. Cannon.2005. Functional domains within the human immunodeficiency virus type 2 envelope protein required to enhance virus production. J. Virol. 79:3627-3638.
2. Adachi, A., et al.1986. Production of acquired immunodeficiency syndromeassociated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 59:284-291.
3. Andrew, A., and K. Strebel.2010. HIV-1 Vpu targets cell surface markers CD4 and BST-2 through distinct mechanisms. Mol. Aspects Med. 31:407-417.
4. Andrew, A. J., E. Miyagi, S. Kao, and K. Strebel.2009. The formation of cysteine-linked dimers of BST-2/tetherin is important for inhibition of HIV-1 release but not for sensitivity to Vpu. Retrovirology. 6:80.
5. Andrew, A. J., E. Miyagi, and K. Strebel.2011. Differential effects of human immunodeficiency virus type 1 Vpu on the stability of BST-2/tetherin. J. Virol. 85:2611-2619.
6. Bour, S., H. Akari, E. Miyagi, and K. Strebel.2003. Naturally occurring amino acid substitutions in the HIV-2 ROD envelope glycoprotein regulate its ability to augment viral particle release. Virology 309:85-98.
7. Bour, S., and K. Strebel.1996. The human immunodeficiency virus (HIV) type 2 envelope protein is a functional complement to HIV type 1 Vpu that enhances particle release of heterologous retroviruses. J. Virol. 70:8285-8300.
8. Cai, D., et al.2009. Up-regulation of bone marrow stromal protein 2 (BST2) in breast cancer with bone metastasis. BMC Cancer 9:102.
9. Casartelli, N., et al.2010. Tetherin restricts productive HIV-1 cell-to-cell transmission. PLoS Pathog. 6:e1000955.
10. Douglas, J. L., et al.2009. Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/tetherin via a {beta}TrCPdependent mechanism. J. Virol. 83:7931-7947.
11. Dubé, M., et al.2010. Antagonism of tetherin restriction of HIV-1 release by Vpu involves binding and sequestration of the restriction factor in a perinuclear compartment. PLoS Pathog. 6:e1000856.
12. Dubé, M., et al.2009. Suppression of tetherin-restricting activity upon human immunodeficiency virus type 1 particle release correlates with localization of Vpu in the trans-Golgi network. J. Virol. 83:4574-4590.
13. Friborg, J., A. Ladha, H. Gottlinger, W. A. Haseltine, and E. A. Cohen.1995. Functional analysis of the phosphorylation sites on the human immunodeficiency virus type 1 Vpu protein. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 8:10-22.
14. Goto, T., et al.1994. A novel membrane antigen selectively expressed on terminally differentiated human B cells. Blood 84:1922-1930.
15. Gupta, R. K., et al.2009. Mutation of a single residue renders human tetherin resistant to HIV-1 Vpu-mediated depletion. PLoS Pathog. 5:e1000443.
16. Gupta, R. K., et al.2009. Simian immunodeficiency virus envelope glycoprotein counteracts tetherin/BST-2/CD317 by intracellular sequestration. Proc. Natl. Acad. Sci. U. S. A. 106:20889-20894.
17. Habermann, A., et al.2010. CD317/tetherin is enriched in the HIV-1 envelope and downregulated from the plasma membrane upon virus infection. J. Virol. 84:4646-4658.
18. Harder, T., P. Scheiffele, P. Verkade, and K. Simons.1998. Lipid domain structure of the plasma membrane revealed by patching of membrane components. J. Cell Biol. 141:929-942.
19. Hauser, H., et al.2010. HIV-1 Vpu and HIV-2 Env counteract BST-2/ tetherin by sequestration in a perinuclear compartment. Retrovirology 7:51.
20. Hinz, A., et al.2010. Structural basis of HIV-1 tethering to membranes by the BST-2/tetherin ectodomain. Cell Host Microbe 7:314-323.
21. Ishikawa, J., et al.1995. Molecular cloning and chromosomal mapping of a bone marrow stromal cell surface gene, BST2, that may be involved in pre-B-cell growth. Genomics 26:527-534.
22. Jia, B., et al.2009. Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2. PLoS Pathog. 5:e1000429.
23. Jolly, C., N. J. Booth, and S. J. Neil.2010. Cell-cell spread of human immunodeficiency virus type 1 overcomes tetherin/BST-2-mediated restriction in T cells. J. Virol. 84:12185-12199.
24. Kawai, S., et al.2008. Interferon-alpha enhances CD317 expression and the antitumor activity of anti-CD317 monoclonal antibody in renal cell carcinoma xenograft models. Cancer Sci. 99:2461-2466.
25. Kawai, S., et al.2006. Antitumor activity of humanized monoclonal antibody against HM1.24 antigen in human myeloma xenograft models. Oncol. Rep. 15:361-367.
26. Klimkait, T., K. Strebel, M. D. Hoggan, M. A. Martin, and J. M. Orenstein.1990. The human immunodeficiency virus type 1-specific protein vpu is required for efficient virus maturation and release. J. Virol. 64:621-629.
27. Kuhl, B. D., et al.2010. Tetherin restricts direct cell-to-cell infection of HIV-1. Retrovirology 7:115.
28. Kupzig, S., et al.2003. Bst-2/HM1.24 is a raft-associated apical membrane protein with an unusual topology. Traffic 4:694-709.
29. Le Tortorec, A., and S. J. Neil.2009. Antagonism to and intracellular sequestration of human tetherin by the human immunodeficiency virus type 2 envelope glycoprotein. J. Virol. 83:11966-11978.
30. Lopez, L. A., et al.2010. Ebola virus glycoprotein counteracts BST-2/tetherin restriction in a sequence-independent manner that does not require tetherin surface removal. J. Virol. 84:7243-7255.
31. Masuyama, N., et al.2009. HM1.24 is internalized from lipid rafts by clathrin-mediated endocytosis through interaction with {alpha}-adaptin. J. Biol. Chem. 284:15927-15941.
32. Mayor, S., K. G. Rothberg, and F. R. Maxfield.1994. Sequestration of GPI-anchored proteins in caveolae triggered by cross-linking. Science 264: 1948-1951.
33. McNatt, M. W., et al.2009. Species-specific activity of HIV-1 Vpu and positive selection of tetherin transmembrane domain variants. PLoS Pathog. 5:e1000300.
34. Mitchell, R. S., et al.2009. Vpu antagonizes BST-2-mediated restriction of HIV-1 release via beta-TrCP and endo-lysosomal trafficking. PLoS Pathog. 5:e1000450.
35. Miyagi, E., A. J. Andrew, S. Kao, and K. Strebel.2009. Vpu enhances HIV-1 release in the absence of Bst-2 cell surface down-modulation and intracellular depletion. Proc. Natl. Acad. Sci. U. S. A. 106:2868-2873.
36. Neil, S. J., S. W. Eastman, N. Jouvenet, and P. D. Bieniasz.2006. HIV-1 Vpu promotes release and prevents endocytosis of nascent retrovirus particles from the plasma membrane. PLoS Pathog. 2:e39.
37. Neil, S. J., T. Zang, and P. D. Bieniasz.2008. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 451:425-430.
38. Ohtomo, T., et al.1999. Molecular cloning and characterization of a surface antigen preferentially overexpressed on multiple myeloma cells. Biochem. Biophys. Res. Commun. 258:583-591.
39. Ono, A., and E. O. Freed.1999. Binding of human immunodeficiency virus type 1 Gag to membrane: role of the matrix amino terminus. J. Virol. 73:4136-4144.
40. Ono, A., and E. O. Freed.2001. Plasma membrane rafts play a critical role in HIV-1 assembly and release. Proc. Natl. Acad. Sci. U. S. A. 98:13925-13930.
41. Ono, K., et al.1999. The humanized anti-HM1.24 antibody effectively kills multiple myeloma cells by human effector cell-mediated cytotoxicity. Mol. Immunol. 36:387-395.
42. Perez-Caballero, D., et al.2009. Tetherin inhibits HIV-1 release by directly tethering virions to cells. Cell 139:499-511.
43. Powles, R., K., et al.2003. Humanized anti-HM1.24 antibody (AHM): phase I study in patients with relapsed or refractory myeloma. Proceedings of the Japanese Multiple Myeloma Forum, 3 November 2003.
44. Ritter, G. D., G. Yamshchikov, S. J. Cohen, and M. J. Mulligan.1996. Human immunodeficiency virus type 2 glycoprotein enhancement of particle budding: role of the cytoplasmic domain. J. Virol. 70:2669-2673.
45. Rong, L., et al.2009. The transmembrane domain of BST-2 determines its sensitivity to down-modulation by HIV-1 Vpu. J. Virol. 83:7536-7546.
46. Sato, K., et al.2009. Comparative study on the effect of human BST-2/ tetherin on HIV-1 release in cells of various species. Retrovirology 6:53.
47. Sauter, D., et al.2009. Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains. Cell Host Microbe 6:409-421.
48. Schindler, M., et al.2010. Vpu serine 52 dependent counteraction of tetherin is required for HIV-1 replication in macrophages, but not in ex vivo human lymphoid tissue. Retrovirology 7:1.
49. Schliemann, C., et al.2010. In vivo biotinylation of the vasculature in B-cell lymphoma identifies BST-2 as a target for antibody-based therapy. Blood 115:736-744.
50. Schubert, H. L., et al.2010. Structural and functional studies on the extracellular domain of BST2/tetherin in reduced and oxidized conformations. Proc. Natl. Acad. Sci. U. S. A. 107:17951-17956.
51. Schubert, U., et al.1996. The two biological activities of human immunodeficiency virus type 1 Vpu protein involve two separable structural domains. J. Virol. 70:809-819.
52. Schubert, U., K. A. Clouse, and K. Strebel.1995. Augmentation of virus secretion by the human immunodeficiency virus type 1 Vpu protein is cell type independent and occurs in cultured human primary macrophages and lymphocytes. J. Virol. 69:7699-7711.
53. Strebel, K., T. Klimkait, F. Maldarelli, and M. A. Martin.1989. Molecular and biochemical analyses of human immunodeficiency virus type 1 vpu protein. J. Virol. 63:3784-3791.
54. Strebel, K., T. Klimkait, and M. A. Martin.1988. A novel gene of HIV-1, vpu, and its 16-kilodalton product. Science 241:1221-1223.
55. Taylor, R. B., W. P. Duffus, M. C. Raff, and S. de Petris.1971. Redistribution and pinocytosis of lymphocyte surface immunoglobulin molecules induced by anti-immunoglobulin antibody. Nat. New Biol. 233:225-229.
56. Terwilliger, E. F., E. A. Cohen, Y. C. Lu, J. G. Sodroski, and W. A. Haseltine.1989. Functional role of human immunodeficiency virus type 1 vpu. Proc. Natl. Acad. Sci. U. S. A. 86:5163-5167.
57. Theodore, T. S., et al.1996. Construction and characterization of a stable full-length macrophage-tropic HIV type 1 molecular clone that directs the production of high titers of progeny virions. AIDS Res. Hum. Retroviruses 12:191-194.
58. Van Damme, N., et al.2008. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 3:245-252.
59. Varthakavi, V., et al.2006. The pericentriolar recycling endosome plays a key role in Vpu-mediated enhancement of HIV-1 particle release. Traffic 7:298-307.
60. Wang, W., et al.2009. HM1.24 (CD317) is a novel target against lung cancer for immunotherapy using anti-HM1.24 antibody. Cancer Immunol. Immunother. 58:967-976.
61. Wang, W., et al.2009. Chimeric and humanized anti-HM1.24 antibodies mediate antibody-dependent cellular cytotoxicity against lung cancer cells. Lung Cancer 63:23-31.
62. Willey, R. L., et al.1988. In vitro mutagenesis identifies a region within the envelope gene of the human immunodeficiency virus that is critical for infectivity. J. Virol. 62:139-147.
63. Yang, H., et al.2010. Structural insight into the mechanisms of enveloped virus tethering by tetherin. Proc. Natl. Acad. Sci. U. S. A. 107:18428-18432.
64. Yang, S. J., et al.2010. Anti-tetherin activities in Vpu-expressing primate lentiviruses. Retrovirology 7:13.
65. Zhang, F., et al.2009. Nef proteins from simian immunodeficiency viruses are tetherin antagonists. Cell Host Microbe 6:54-67.